Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence